VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (the “Company” or “WuXi AppTec”) on a voluntary basis.

We have noticed that WuXi AppTec was named in a draft version of the Biosecure Act (the “Draft Bill”) introduced in the U.S. House of Representatives (the “House”) on January 25, 2024. There was also a similar draft bill recently introduced in the U.S. Senate. The Draft Bill has not been enacted into law and the legislative process requires the House and the U.S. Senate, after separate review by relevant committees in the House and the Senate, to vote on their respective versions of the bill and then agree on a final version. Therefore, the contents of the Draft Bill, including the reference to the Company, remain subject to further review and changes. We are working closely with our advisors to monitor the legislative process of the Draft Bill.

The Company notes that the Draft Bill contain certain alleged findings against WuXi AppTec. We believe such alleged findings are neither legitimate nor accurate. We are confident that the business development of WuXi AppTec will not pose a security risk to any country.

WuXi AppTec has been committed to abiding by laws and regulations in the countries in which we operate, including in both China and the U.S.. By adhering to our core value of “doing the right thing and doing it right”, we have served as a trusted partner in the global healthcare community, where for more than twenty years the Company has helped thousands of American and global customers with discovery, development, and manufacturing efforts to deliver innovative medicines that save and improve patients’ lives. We look forward to continuing to serve customers and help patients around the world.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, January 26, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* For identification purposes only